Promising trial: Viagra-like drug succeeds in slowing Alzheimer's decline
An advanced global trial found that the experimental drug AR1001, similar to Viagra, slowed cognitive decline by 31% among 604 early-stage Alzheimer's patients. The developing company plans to discuss the findings with the FDA.
An advanced global clinical trial found that the experimental drug AR1001, structurally similar to Viagra, slowed cognitive decline and memory loss by 31% among 604 patients in the early stages of Alzheimer's disease who were not taking other treatments. The drug, developed by South Korean biotech company AriBio, belongs to the PDE5 inhibitor family and works by relaxing blood vessels and increasing blood flow to the brain. The trial was conducted in 13 countries, and most side effects were mild to moderate. Richard Oakley from the Alzheimer's Society described the results as an exciting sign of a new treatment but warned against taking Viagra for this purpose. The company plans to discuss the findings with the FDA. Experts emphasized that further research is needed before the drug can be offered to patients.
Promising trial: Viagra-like drug succeeds in slowing Alzheimer's decline